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Abstract
Background There is limited understanding of the health
economic implications of cervical screening with human
papillomavirus (HPV)-16/18 genotyping.
Objective The aim of this study was to evaluate the cost
effectiveness of cervical cancer primary screening with a
HPV-16/18 genotyping test which simultaneously detects
12 other high-risk HPV types.
Methods A Markov cohort model compared four strate-
gies: (1) cytology with reflex HPV testing for atypical
squamous cells of undetermined significance (ASC-US);
(2) co-testing with cytology and HPV testing; (3) HPV with
reflex to cytology; and (4) HPV with 16/18 genotyping and
reflex cytology (ASC-US threshold). Screening began at
age 30 and was performed triennially over 40 years.
Screening sensitivity and specificity values for cervical
intraepithelial neoplasia (CIN) 3 were obtained from the
Addressing THE Need for Advanced HPV Diagnostics
(ATHENA) trial. Outcomes for a 1-year follow-up scenario
wherein persistent disease was detected were estimated.
Screening and cancer treatment costs were calculated from
a US payer’s perspective in 2013. Costs and quality-
adjusted life-years (QALYs) were discounted at 3 %
annually.
Results Applying a US$50,000/QALY threshold, strategy
(4) dominated strategies (2) and (3) by reducing costs and
cancer incidence and improving QALYs, and was cost
effective versus strategy (1). Accounting for persistent
CCIN 3 at 1 year, strategy (4) was cost effective versus all
other strategies. Detecting HPV-16/18 resulted in earlier
diagnosis of clinically relevant CCIN 3 at initial screening
and efficient use of follow-up resources. Outcomes were
most influenced by strategy performance.
Conclusions Incorporating HPV-16/18 genotyping is cost
effective and may improve detection of CIN, thereby pre-
venting cervical cancer.
Key Points for Decision Makers
Access to cervical cancer screening strategies that
facilitate early detection of clinically relevant
cervical intraepithelial neoplasia associated with
HPV-16/18 allows women to seek treatment sooner
and may thereby improve cancer protection.
Stratifying cancer risk via HPV-16/18 genotyping in
women aged C30 years may be cost saving
compared with cotesting with cytology and HPV
testing by reducing the number of screening tests and
overall screening costs.
HPV-16/18 genotyping with reflex cytology is cost
effective in cervical screening and represents a
beneficial alternative approach to cervical screening
from both a health and economic perspective.
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1 Introduction
Organized screening programs aimed at early detection of
high-grade cervical intraepithelial neoplasia (CIN) have
steadily reduced cervical cancer mortality (Alliance for
Cervical Cancer Prevention, Preventing Cervical Cancer
Worldwide, 2004). Nonetheless, individual screening tests
can suffer from shortcomings, particularly when applied
indiscriminately to the general screening population. Sub-
jective interpretation of Pap cytology (‘cytology’) renders a
high degree of variability [1]. In populations with low
prevalence of human papillomavirus (HPV), cytology
demonstrates low sensitivity and poorer positive predictive
value due to fewer high-grade lesions [1]. Also, primary
HPV pooled testing exhibits lower specificity in excluding
the absence of high-grade CIN [2]. Accordingly, ongoing
efforts aim to identify strategies incorporating more pru-
dent use of individual screening tests.
Since HPV-16 and HPV-18 account for more than 70 %
of cervical cancer cases [3, 4] and confer a higher risk for
neoplasia [5], testing for these genotypes may be clinically
useful for stratifying cancer risk [6]. A qualitative in vitro
assay (cobas HPV Test), which simultaneously detects 14
high-risk HPV types and provides specific genotyping
information for HPV-16 and HPV-18, was validated in the
Addressing THE Need for Advanced HPV Diagnostics
(ATHENA) trial [6, 7]. The trial concluded that primary
HPV testing and triage of HPV-positive women with HPV-
16/18 genotyping and cytology may balance screening
benefits and harms by maximizing sensitivity while limit-
ing the number of diagnostic tests [7]. The US Food and
Drug Administration recently approved the cobas HPV
Test for primary cervical cancer screening in women aged
C25 years. To explore the economic implications, we
compared the relative cost effectiveness of HPV-16/18
genotyping and three other primary cervical screening
strategies.
2 Materials and Methods
2.1 Study Population
The model evaluated the outcomes of a hypothetical cohort
of 1,000 non-hysterectomized women who were asymp-
tomatic for cervical cancer and had participated in cervical
screening in a US healthcare setting over a 40-year period.
The starting age of the cohort was 30 years. Because the risk
of HPV persistence increases with age [8], HPV testing in
women aged C30 years may identify more clinically sig-
nificant infections and, therefore, the performance of HPV-
16/18 genotyping in this population is of particular interest.
2.2 Comparator Screening Strategies
We assessed the cost effectiveness of four primary cervical
screening strategies: (1) cytology with reflex HPV testing
for triage of atypical squamous cells of undetermined sig-
nificance (ASC-US) (‘Cytology’); (2) co-testing with
cytology and HPV testing (‘Co-testing’); (3) HPV with
reflex cytology for positive HPV (‘HPV HR [human pap-
illomavirus, high-risk] Only’); and (4) HPV with 16/18
genotyping and reflex cytology (ASC-US threshold) (‘HPV
with Genotyping’). (See Fig. 1 for detailed algorithms).
Cytology and Co-testing were selected based on the
American Cancer Society (ACS)–American Society for
Colposcopy and Cervical Pathology (ASCCP)–American
Society of Clinical Pathologists (ASCP) guidelines. These
strategies represented practices most likely to be imple-
mented in community settings [9, 10].
Routine screening was performed triennially with some
women returning for 1-year retesting based on primary
screening results. We assumed that all women complied
with scheduled screening visits as well as recommenda-
tions for colposcopy and biopsy. For all strategies, women
with false positive results returned for follow-up screening
as recommended by the ASCCP [9]. Women exited
screening at age 70 years in the model based on clinical
guidelines advising cessation of screening after the age of
65 years, but extending beyond age 65 for women with a
history of CIN 2, CIN 3, or cervical cancer [9].
2.3 Markov Model Structure and Health States
The Excel-based Markov cohort model (Microsoft Corpo-
ration, Redmond, Washington) incorporated a ‘no-screen-
ing’ model which simulated the natural history of
oncogenic HPV infection in an unscreened population.
This natural history model served as the framework within
which the effects of each screening strategy were applied
and the outcomes compared. Since the analysis reflected
clinical practice in the US, ‘no screening’ was not con-
sidered a comparator option.
Applying literature-based transition probabilities [11–
19], women transitioned annually across seven possible
states: (1) No high-risk HPV infection; (2) High-risk HPV
infection (no CIN); (3) CIN 1; (4) CIN 2; (5) CIN 3 or
worse; (6) Cervical Cancer, and (7) Dead (Fig. 2). At
baseline, the cohort was apportioned among the Markov
states based on the age-adjusted prevalence of high-risk
HPV infection, the probability of CIN, and the age-adjus-
ted cervical cancer incidence (Table 1). Age-specific
probabilities for high-risk HPV infection and CIN clear-
ance, progression, and regression were obtained from
published epidemiologic, cost-effectiveness, and mathe-
matical models simulating HPV infection and cervical
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carcinogenesis (Table 1) [17–23]. Annual transition prob-
abilities for progression to CIN 2 and CCIN 3 from no CIN
were computed from the 36-month cumulative hazard rate
for progression from incident HPV-16 infection to CIN 2
and CCIN 3 (16.5 %) reported for the placebo arm
(n = 42) in a randomized controlled trial of a HPV-16
vaccine [21]. Progression to invasive cervical cancer
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analysis of cervical screening
strategies in non-
hysterectomized women aged
C30 years: primary screening
algorithms. a Cytology with
reflex HPV at ASC-US
threshold (‘Cytology’) (Women
who had ASC-US during
primary screening with
Cytology were triaged to HPV
testing, whereas those with
cytology findings worse than
ASC-US were referred to
colposcopy). b Co-screening
with reflex for ASC-US (‘Co-
testing’) (In Co-testing, women
were referred to colposcopy if
they had either (i) ASC-US and
a positive HPV test, or (ii)
cytology worse than ASC-US
regardless of HPV status).
c HPV with reflex to cytology at
ASC-US threshold (‘HPV HR
Only’) (In HPV HR Only, all
women who tested positive for
HPV were further evaluated
with cytology. Those with
normal cytology were retested
in 1 year, whereas women
exhibiting ASC-US or worse
were referred to colposcopy).
d HPV-16/18 genotyping and
reflex cytology at ASC-US
threshold (‘HPV with
Genotyping’) (Women with
HPV-16 or HPV-18 detected by
HPV with Genotyping during
primary screening were referred
for immediate colposcopy,
whereas those testing positive
for other high-risk HPV
genotypes but with normal
cytology were retested at
1 year). ASC-US atypical
squamous cells of undetermined
significance, HPV human
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regression from Cervical Cancer to the CIN states did not
occur. Given that we primarily intended to address the
screening effect of HPV with Genotyping, we did not
stratify Cervical Cancer by stage; rather, we modeled
health states for pre-cancer lesions arising from persistent
HPV infection. Other models utilizing a single health state
to depict invasive cervical cancer have also been published
in the literature [24, 25].
The no-screening model was manually calibrated to
approximate published estimates of cervical cancer incidence
and mortality in an unscreened population. In calibrating a
natural history model for HPV infection and cervical cancer,
Taylor et al. [26] noted that manual calibration was one of two
methods achieving the best fit, yielding a 10 % mean devia-
tion from optimal fit. Our final model generated an annual
cervical cancer incidence of approximately 19.47 cases per
100,000 women-years. This projection was 10.1 % higher
than the age-standardized incidence rate of 17.70 per
100,0000 women-years for an unscreened US population cited
by Gustafsson et al. [27], but 1.1 % lower than the incidence
(20.64 per 100,000) predicted by a cost-effectiveness
screening model by Vijayaraghavan et al. [11].
Age-adjusted annual probabilities of death for women
without cervical cancer were derived from the general
population estimates reported in the US Social Security
Actuarial Publications Period Life Table. To estimate
cervical cancer mortality in the unscreened population, the
age-specific 5-year relative cervical cancer survival rates
reported by the National Cancer Institute Surveillance
Epidemiology and End Results (SEER) Cancer Statistics
Review (1975–2007) were converted to annual probabili-
ties and multiplied by the respective annual numbers of
expected cervical cancer cases [28]. Our model estimated
an annual cervical cancer mortality rate of 15.5 per 100,000
unscreened women. Published cervical cancer mortality
rates in unscreened populations vary by geographic local-
ity, population age, and study year, but have exceeded 20
deaths per 100,000 women in some studies [29]. For the
screening cohorts, women who were diagnosed with cer-
vical cancer were assigned a 5-year relative survival rate of
90 % per the ACS based on the assumption that cancers in
asymptomatic women receiving regular screening with
100 % compliance would tend to be early-stage, curable
cancers (ACS, Cancer Facts and Figures, 2010) [30].
In addition to face validation of the no-screening model,
analytical methods (including programming, coding, and
equations), configuration of screening algorithms, screen-
ing results, and costs were reviewed by individuals with
expertise in the area of cervical cancer screening (including
two clinicians) and were found to be reasonable within the
structural limitations of a Markov cohort model.
2.4 Model Inputs
2.4.1 Screening Performance and Key Assumptions
Baseline performance values were obtained from the














Fig. 2 Markov health states for




98 W. K. Huh et al.
cohort study for HPV-16/18 genotyping which included
more than 47,000 women ages C21 years from clinical
sites across 23 states [7, 12]. A subanalysis of 34,254
participants aged C30 years (mean 44.7 years) compared
ten different cervical screening strategies for detecting
high-grade cervical disease [7]. In addition to HPV-16/18
genotyping, the analyses evaluated strategies without HPV-
16/18 genotyping that were considered of interest in clin-
ical practice (several of which were included in the present
model). Given the large cohort, expected frequency of CIN
[12], and pertinent strategies evaluated in a single popu-
lation, the ATHENA trial was considered an appropriate
source for screening performance data.
Screening performance was defined as the sensitivity
and specificity for CCIN 3 and referred to overall strategy
performance as opposed to that of component tests. Since
approximately 90 % of CIN 1 and 88 % of CIN 2 cases
regress within 1 year [31, 32], the model accounted only
for sensitivity in detecting incident and persistent cases of
CCIN 3. At publication, the ATHENA analysis reported
only the baseline performance of the strategies as repre-
senting usual clinical practice. Thus, comparing the ‘true’
sensitivities (defined as performance achieved by com-
pleting a full screening cycle) was not feasible since
outcomes could be only partially ascertained from the
initial screening. Therefore, we examined a scenario
wherein all cases deferred at baseline returned for 1-year
follow-up. Screening sensitivities were re-calculated by
assuming that deferred CCIN 3 cases would be captured at
the 1-year visit. Detecting additional CCIN 3 effectively
increased the overall sensitivities of the strategies, partic-
ularly those deferring more patients at baseline; this
resulted in similar performance between the HPV with
Genotyping and HPV HR Only strategies and improved
sensitivity for co-testing (Table 2).
2.4.2 Costs
Costs were modeled from the perspective of the US
healthcare payer and reported in 2013 US dollars (Table 2).
Unit costs represented the median national Medicare pay-
ments for the respective Common Procedural Terminology
codes (Centers for Medicare and Medicaid Services Phy-
sician Fee Schedule, 2013). For each strategy, the total
annual cost included the costs for screening (including
routine examinations, triage, and retesting) and treatment
for CIN and cervical cancer. Screening costs included the
costs for individual tests and office visits. Screening and
Table 1 Model assumptions for the prevalence of high-risk HPV, HPV-16/18, and health state transition probabilities by age group
Age group (years) Reference(s)
25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–70
Prevalence
HPV HR, % infected 21.1 13.4 9.9 7.6 6.6 6.6 5.9 5.9 4.4 ATHENA [12]
HPV-16/18, % of HPV HR 33.0 28.6 27.9 20.3 23.8 19.9 19.3 18.1 18.9 ATHENA [12]
HPV HR, % per cytology
Normal 16.6 10.6 7.5 6.1 5.4 5.6 5.0 5.3 4.0 ATHENA [12]
ASC-US 49.4 31.2 28.5 19.8 9.8 18.8 20.3 20.0 12.5 ATHENA [12]
LSIL/HSIL 78.7 72.6 69.0 61.5 60.6 56.1 65.5 50.0 66.7 ATHENA [12]
Annual transition probabilities used in the model
HPV HR (-) to HPV HR (?) 0.1500 0.0576 0.0333 0.0333 0.0333 0.0222 0.0222 0.0222 0.0222 [17, 20, 23]
HPV HR (?) to HPV HR (-) 0.7000 0.4130 0.4130 0.4130 0.4130 0.4130 0.4130 0.4130 0.4130 [17, 20–22]
HPV HR (?) no CIN to CIN1 0.1100 0.1100 0.1100 0.1100 0.1100 0.1100 0.1100 0.1100 0.1100 [18, 20]
HPV HR (?) no CIN to CIN
2 or CIN 3
0.0583 0.0583 0.0583 0.0583 0.0583 0.0583 0.0583 0.0583 0.0583 [18, 21]
CIN 1 to CIN 2 or CIN 3 0.0198 0.0198 0.1444 0.1444 0.2688 0.2688 0.2688 0.2688 0.2688 [19, 21]
CIN 2 or CIN 3 to Cervical
Cancer
0.0060 0.0060 0.0060 0.0060 0.0060 0.0060 0.0060 0.0060 0.0060 [18, 20, 21]
CIN1 to HPV HR (?) or HPV
HR (-)
0.2248 0.2248 0.1124 0.1124 0.1124 0.1124 0.1124 0.1124 0.1124 [17]
CIN 2 or CIN 3 to CIN1 0.2340 0.2340 0.2340 0.2340 0.2340 0.2340 0.2340 0.2340 0.2340 [17, 20]
CIN 2 or CIN 3 to HPV
HR (-)
0.2036 0.2036 0.2036 0.2036 0.1901 0.1901 0.1901 0.1901 0.1901 [17]
ASC-US atypical squamous cells of undetermined significance, ATHENA Addressing THE Need for Advanced HPV Diagnostics, CIN cervical
intraepithelial neoplasia, HPV human papillomavirus, HR high risk, HSIL high-grade squamous intraepithelial lesion, LSIL low-grade squamous
intraepithelial lesion
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treatment costs were calculated by multiplying the relevant
unit costs by the respective expected percentages of women
utilizing each test or treatment in the strategy, and then
summing the utilization-weighted costs.
2.4.3 Health Utilities
Quality-adjusted life-years (QALYs) were calculated by
multiplying the expected number of life-years gained by
the assigned health utility for each Markov state (Table 2).
Health utility values for the CIN 1 and the CIN 2 and CIN 3
states represented the utilities for low-grade squamous
intraepithelial lesions and high-grade squamous intraepi-
thelial lesions, respectively, as cited by Sanders et al. [18]
and applied to the US population in a study by the Institute
of Medicine (IOM) [33]. In the latter study, Health Utilities
Mark II utilities, which were derived for a general Cana-
dian population via the standard gamble method, were
assigned quality-adjusted weights to valuate various mor-
bidity states in the US [33]. To avoid overestimating the
utility for Cervical Cancer, we assigned a base value of
0.71 which represented the mean weighted health utility for
cervical cancer in the treatment phase (0.79 for Stage I and
0.62 for Stages II-IV per Sanders et al.) adjusted by the
SEER stage distribution for cervical cancer at diagnosis
(see Table 2) [19, 28]. We assumed a 1-year disutility for
detected but asymptomatic cervical cancer cases [19].
2.5 Model Outcomes
Outcomes included direct medical costs and QALYs cal-
culated over 40 years and discounted at a yearly rate of
3.0 % [34, 35]. Cost effectiveness was expressed as the
incremental cost-effectiveness ratio (ICER), which repre-
sented the additional cost per QALY gained using one
strategy versus the next non-dominated strategy, and
assessed against the payer’s willingness-to-pay (WTP)
criterion of US$50,000/QALY. Other outcomes included
the undiscounted number of life-years gained, annual cer-
vical cancer incidence, and mortality rate (per 100,000
women) for each strategy. Additionally, we determined the
expected number of colposcopies required to detect one
case of CCIN 3, an endpoint considered by the ACS-AS-
CCP-ASCP guidelines as a primary surrogate for the
potential harm of cervical screening [9].
2.6 Sensitivity Analyses
We employed one-way sensitivity analyses to assess the
impact of key inputs on the relative cost effectiveness of
HPV with Genotyping versus the comparators. The
resulting tornado diagrams depicted the degree of influence
of each parameter on the relative cost effectiveness of HPV
with Genotyping when tested at high (?10 %) and low
(-10 %) values; wider bars indicated greater influence.
Additionally, we performed threshold analyses using an
Excel what-if analysis function to examine the effects of
further increasing or decreasing parameters exhibiting
greater influence on visual inspection or those of particular
interest (such as sensitivity and costs).
To quantify the likelihood that HPV with Genotyping is
cost effective compared with the non-dominated strategies,
probabilistic sensitivity analysis (PSA) was performed by
simultaneously varying key inputs across values sampled
1,000 times from assigned distributions (Table 2). We
applied a standard error (SE) of 1.0 % for sensitivities and
specificities (based on the ATHENA data [n = 34,254]),
and in the absence of other data, assumed a SE of 10 % the
deterministic value for costs, health utilities, and the annual
discount rate for costs and effects. The resulting cost-
effectiveness acceptability curve showed the percentage
likelihood that the strategy was cost effective when
assessed against WTP threshold criteria. We used the net
monetary benefit (NMB), a measure deemed appropriate by
the International Society for Pharmacoeconomics and
Outcomes Research, for generating the results of the PSA
[36]. When comparing two strategies, the strategy gener-
ating a greater NMB (positive incremental NMB [INMB])
was considered more cost effective.
3 Results
In the primary analysis, HPV with Genotyping was more
effective and less costly compared with both Co-testing
and HPV HR Only, thereby dominating the two strategies
(Table 3). Compared with Cytology, HPV with Genotyp-
ing was cost effective, generating an acceptable ICER of
US$7,667/QALY. Further, HPV with Genotyping appeared
beneficial in reducing annual cervical cancer incidence and
mortality rates compared with the other strategies, while
requiring a relatively moderate number of colposcopies for
each CCIN 3 detected (Table 3).
As shown in Table 4, women were more frequently
triaged with Cytology when HPV HR Only was employed
for primary screening compared with HPV with Genotyp-
ing. Similarly, fewer women screened with HPV with
Genotyping were deferred to 1-year retesting compared
with those triaged in both HPV HR Only and Co-testing.
Examining the expenditures (data not shown), the average
total costs which included routine and repeat screening,
triage tests (for HPV HR Only), colposcopy, and biopsy,
were higher for Co-testing and HPV HR Only (US$1,737
and US$1,481, respectively) compared with Cytology and
HPV with Genotyping (US$1,001 and US$1,064,
respectively).
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Similar trends were observed in the second scenario.
Despite equivalent sensitivities, HPV with Genotyping
resulted in fewer women being triaged and deferred to
follow-up compared with HPV HR Only, yielding lower
average screening costs (US$1,063 versus US$1,463,
respectively) and an average cost-savings of US$400 per
Table 2 Key model inputs and assumptions
Variable Base Range Distribution Reference(s)
Annual discount rate
Effects and costs 3.0 % 2.7–5.0 % Normal Assumption
Unit costs (2013 USD)
Office visit (routine/repeat screening) $72.81 $65.53–$80.09 Normal CPT 99213 (office visit, established patient)
Cytology $27.85 $25.07–$30.64 Normal CPT 88142, 88143 (cytopathology, cervical or vaginal)
HPV DNA pooled test $48.24 $43.42–$53.06 Normal CPT 87621 (agent detection by nucleic acid;
papillomavirus, human, amplified probe technique)
HPV-16/18 genotyping test $48.24 $43.42–$53.06 Normal Same as above
Colposcopy plus biopsy $287.67a $258.90–$316.44 Normal CPT 57455 (colposcopy and biopsy of cervix)
Treatment for CCIN 3 $1,292b $1,162–$1,421.20 Normal [11]
Cervical cancer treatment $47,840b $40,445–$49,432.90 Normal [11, 16]
Sensitivity for CCIN 3
Cytology (with reflex HPV test [ASC-US]) 56.1 % 50.5–61.7 % Beta ATHENA [7]
HPV with genotyping (reflex cytology
[ASC-US])
72.0 % 64.8–79.2 % Beta ATHENA [7]
HPV HR only (with reflex to cytology) 51.9 % 46.7–57.1 % Beta ATHENA [7]
Co-testing (with reflex for ASC-US) 56.1 % 50.5–61.7 % Beta ATHENA [7]
Specificity for CCIN 3
Cytology (with reflex HPV test [ASC-US]), 87.6 % 78.8–96.4 % Beta ATHENA [7]
HPV with genotyping (reflex cytology
[ASC-US])
85.2 % 76.7–93.7 % Beta ATHENA [7]
HPV HR only (with reflex to cytology) 91.3 % 82.2–100 % Beta ATHENA [7]
Co-testing (with reflex for ASC-US) 87.6 % 78.8–96.4 % Beta ATHENA [7]
Estimated sensitivities for 1-year follow-up scenario Base (%) Range Distribution Formula for calculationc
Cytology (with reflex HPV test [ASC-US])d 56.1 (106 ? 0)/189 = 56.1 %
HPV with genotyping (reflex cytology [ASC-US]) 89.9 (136 ? 34)/189 = 89.9 %
HPV HR only (with reflex to cytology) 89.9 (98 ? 72)/189 = 89.9 %
Co-testing (with reflex for ASC-US) 94.2 (106 ? 72)/189 = 94.2 %
Health utilities Base Range Distribution Reference(s)
Well 1.0 0.90–1.0 Beta [19]
CIN 1 0.97 0.87–1.0 Beta [19]
CIN 2 0.97 0.87–1.0 Beta [19]
CIN 3 0.97 0.87–1.0 Beta [19]
Cervical cancer 0.71e 0.64–0.78 Beta [19, 28]
ASC-US atypical squamous cells of undetermined significance, ATHENA Addressing THE Need for Advanced HPV Diagnostics, CIN cervical intraepithelial
neoplasia, CPT common procedural terminology, DNA deoxyribonucleic acid, HPV human papillomavirus, HPV HR human papillomavirus, high-risk, SEER
National Cancer Institute Surveillance Epidemiology and End Results, USD United States dollars
a Estimated cost includes physician’s fee (CPT 88305, US$70.09). Model assumed ratio of colposcopies to biopsies = 1.5; 82.6 % of colposcopy/biopsy
procedures were performed in physicians’ offices and 17.4 % were performed in hospital outpatient settings
b Costs were adjusted to 2013 USD using the medical component of the Consumer Pricing Index
c Adjusted sensitivity values were calculated as (baseline ? 1-year follow-up)/total C CIN 3, where baseline and 1-year follow-up signified the number of
CCIN 3 cases detected at baseline screening and 1-year follow-up, respectively, and total CCIN 3 (denominator) indicated the total cumulative number of
CCIN 3 cases prevalent in the ATHENA trial cohort as confirmed by colposcopy and valid biopsy
d This strategy does not include retesting at 1 year. Women with[ASC-US or who have ASC-US and are high-risk HPV-positive are referred for immediate
colposcopy
e Assumption was based on health utilities for cervical cancer in treatment phase (0.79 for Stage I and 0.62 for Stages II–IV), weighted by SEER stage
distribution for cervical cancer at diagnosis; value represents weighted mean health utility. Assumed 5 % unstaged patients were distributed as follows: 2 %
local; 2 % regional; and 2 % distant disease
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woman screened. Co-testing generated a marginal QALY
gain but was more costly than HPV with Genotyping and,
by comparison, not cost effective.
In the one-way sensitivity analyses, changes in the
health utilities and screening sensitivities had the largest
impact on the relative cost effectiveness of HPV with
Genotyping compared with the comparators (Fig. 3). HPV
with Genotyping appeared more cost effective when lower
utilities were assigned to the CIN and Cervical Cancer
states, but remained cost effective even when the utilities
were increased to 1.0. As presented in Table 5, threshold
analyses showed that under the current assumptions and a
WTP criterion of US$50,000, HPV with Genotyping was
less cost effective than the comparators only when (i) the
current cost for HPV-16/18 genotyping was more than
tripled, or (ii) the sensitivity of HPV with Genotyping was
reduced by C50 % of the current estimate, or (iii) the
sensitivity of Cytology approached 100 %. Compared with
Cytology, the only other non-dominated strategy, the PSA
showed that, at a WTP threshold of US$50,000/QALY as
well as with more stringent payer criteria, HPV with
Genotyping was cost effective (Fig. 4).
4 Discussion
Stratifying cervical cancer risk via HPV-16/18 genotyping
may constitute a cost-effective approach for primary
screening in women aged C30 years. Under the current
assumptions, this strategy conferred incremental QALY
gains and reduced cervical cancer incidence and mortality,
but on average, was less expensive compared with HPV
HR Only and Co-testing. HR HPV Only yielded additional
re-testing and diagnostic visits and incurred higher costs
in the long run compared with HPV with Genotyping.
Co-testing was most costly as both routine and follow-up
screening required dual testing with HPV and cytology
tests. Although more costly than Cytology, HPV with
Genotyping improved clinical outcomes, thereby main-
taining cost effectiveness.
Because baseline sensitivities were obtained from initial
screening in the ATHENA trial, the values were adjusted to
account for detecting new and persistent CCIN 3 at 1 year.
It was expected that strategies deferring intermediate-risk
women to 1-year follow-up would capture additional per-
sistent CCIN 3. This assumption was supported by the
HPV FOCAL trial which showed that CCIN 3 detection
rates at 1 year were increased in women who had been
initially high-risk HPV-positive and cytology-negative
[37]. Despite identical sensitivities for CCIN 3 in this
scenario, HPV with Genotyping was cost-saving over HPV
HR Only again by reducing the frequency of triage and
follow-up tests. Although both strategies deferred women
who were initially negative for intraepithelial lesion and
malignancy to 1-year follow-up, HPV HR Only retested all
high-risk HPV-positive women whereas HPV with Geno-
typing retested a smaller subgroup that was positive for
non-16/18 high-risk HPV only. Likewise, triage was
restricted to women positive for non-16/18 high-risk HPV
only in the latter, but included all women positive for high-
risk HPV in the former. Stratifying high-risk patients with
16/18 genotyping at baseline initially incurred relatively
higher routine screening and diagnostic costs, but resulted
in fewer highest-risk patients in the long term, thereby
reducing costs. Consistent with a prior lifetime model [11],
triennial Co-testing increased QALYs in the second
Table 3 Cost effectiveness and outcomes of four cervical screening strategies in women aged C30 years
Screening strategy Discounted ICER Cervical cancer Undiscounted
Costa QALYs ($/QALY)a Incidenceb Mortalityb Life-years
Base case
Cytology (reflex HPV test for ASC-US) $1,230 22.856 – 13.31 4.64 37.978
HPV with genotyping (reflex cytology [ASC-US]) $1,367 22.874 $7,667 9.47 3.33 37.984
HPV HR only (with reflex to cytology [ASC-US]) $1,749 22.866 Dominated 11.14 3.91 37.981
Co-testing (with cytology and HPV testing) $2,014 22.868 Dominated 10.74 3.77 37.982
1-year follow-up scenario
Cytology (reflex HPV test for ASC-US) $1,230 22.856 – 13.31 4.64 37.978
HPV with genotyping (reflex cytology [ASC-US]) $1,389 22.879 $6,910 8.38 2.95 37.985
HPV HR only (with reflex to cytology [ASC-US]) $1,789 22.879 Dominated 8.38 2.95 37.985
Co-testing (with cytology and HPV testing) $2,059 22.880 $661,933 8.17 2.88 37.986
ASC-US atypical squamous cells of undetermined significance, HPV human papillomavirus, HPV HR human papillomavirus, high-risk, ICER
incremental cost-effectiveness ratio, QALY quality-adjusted life-year, USD United States dollars
a 2013 USD
b Annual rate per 100,000 women
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scenario, but was more costly than HPV with Genotyping,
mainly due to the greater number of initial tests.
Our analysis is noteworthy as it incorporated data from
over 34,000 women aged C30 years participating in the
largest US diagnostic accuracy cohort study for cervical
screening to date. Contrary to other models, we employed
screening performance inputs from a single trial. Screening
performance can vary between clinical trials, impacted by
factors such as study design, disease prevalence, and sta-
tistical methods. Applying data from the ATHENA trial
facilitated comparison of the relative performance of the
strategies within the same cohort, thereby reducing
variability.
We note several limitations. First, excluding the impact
of non-compliance at follow-up may have over-estimated
screening sensitivities and costs, particularly for Co-testing
and HPV HR Only, which deferred more patients to re-
testing. Second, we did not examine co-testing every
5 years because while this is a preferred strategy for
women aged 30–65 years, the American Congress of
Obstetricians and Gynecologists and other clinical experts
have contended that triennial co-testing is the more likely
scenario in the community as patients are unlikely to feel
comfortable with extended screening intervals [10]. Thus,
we believe co-testing every 3 years is relevant for a US
model. Nevertheless, we recognize that screening practices
may vary considerably, the effects of which may be
investigated in future research.
Under the current assumptions, we projected cervical
cancer incidence rates which exceeded the 2007–2011 US
age-adjusted incidence of 7.8 per 100,000 reported by the
SEER. However, our model included non-hysterectomized
women aged C30 years only. Rositch et al. [38] reported
hysterectomy-corrected age-standardized cervical cancer
incidence rates in the US. For the age groups spanning
from 30 to 74 years, incidence rates (per 100,000) ranged
from 11.5 to 27.4 following correction for hysterectomy
prevalence [38], which was higher than our model results.
These findings indicate that cervical cancer incidence may
be higher than the national estimate when correcting for
hysterectomy, implying the need for appropriate adjust-
ments when evaluating cervical screening outcomes.
Annual cervical cancer mortality rates in the model
exceeded the 2006–2010 SEER age-adjusted rate of 2.4 per
100,000 women. While the effects of hysterectomy prev-
alence on cervical cancer mortality rates have not been
extensively investigated, an early study by the Centers for
Disease Control and Prevention found that correcting for
hysterectomy prevalence resulted in a 39 % relative
increase in cervical cancer mortality rates in the US during
the period 1965–1988 [39]. We assumed that cancers were
detected at an earlier stage in the screened population,
which was associated with 90 % 5-year relative survival.
However, this may have overestimated the projected sur-
vival benefits of screening. Various sources have reported
5-year relative survival rates of 95 % for screen-detected
asymptomatic cervical cancers [30] and between 68 and
75 % for patients with symptomatic presentations,
although the latter would not likely represent the majority
of the model population (ACS Cancer Facts and Figures,
2014; US National Institutes of Health Fact Sheet, Cervical
Cancer, 2010) [30]. Further consideration of disease
severity upon detection is required to more precisely pre-
dict mortality rates.
Table 4 Expected annual number of cervical screening examinations and colposcopies required for detecting CCIN 3 in the base case and
1-year follow-up scenario
Strategy Number of screening examinationsa,b No. of colposcopies per CCIN 3 detected
Routine Triage Retest Colposcopies
Base case
Cytology (reflex HPV test for ASC-US) 30,364 1,282 0 2,104 4.76
HPV with genotyping (reflex cytology [ASC-US]) 23,065 6,372 1,024 2,159 3.06
HPV HR only (with reflex to cytology [ASC-US]) 22,872 8,405 6,557 2,339 3.95
Co-testing (with cytology and HPV testing) 22,848 0 6,686 2,967 4.79
1-year follow-up scenario
Cytology (reflex HPV test for ASC-US) 30,294 1,282 0 2,104 4.76
HPV with genotyping (reflex cytology [ASC-US]) 23,201 6,265 1,021 2,130 2.73
HPV HR only (with reflex to cytology [ASC-US]) 23,201 8,079 6,332 2,249 2.89
Co-testing (with cytology and HPV testing) 23,161 0 6,479 2,915 3.67
ASC-US atypical squamous cells of undetermined significance, CIN cervical intraepithelial neoplasia, HPV human papillomavirus, HPV HR
human papillomavirus, high-risk
a Per 100,000 women and annualized over a 40-year time horizon
b Triage tests included HPV test for Cytology and cytology for both HPV with genotyping and HPV HR only
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Fig. 3 One-way sensitivity analysis: tornado diagrams of INMB of
HPV-16/18 genotyping with reflex cytology (‘HPV with Genotyp-
ing’) versus alternative primary cervical screening strategies. The
INMB of HPV with Genotyping compared with Cytology (a), HPV
HR Only (b), and Co-testing (c) decreased primarily when higher
values were assigned to the health utilities for the CIN states, or when
screening performance (sensitivity) was improved for the comparator
strategies or reduced for HPV with Genotyping. The INMB was
calculated based on a WTP threshold of $50,000 per QALY and
represented the difference between the net monetary benefit of the
two strategies. CIN cervical intraepithelial neoplasia, DNA deoxyri-
bonucleic acid, HPV human papillomavirus, HPV HR human
papillomavirus, high-risk, INMB incremental net monetary benefit,
QALY quality-adjusted life year, WTP willingness-to-pay
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Lastly, we did not consider HPV immunization effects,
which would theoretically decrease the prevalence of high-
risk HPV and thereby reduce the sensitivity of the HPV
strategies. Analyses of data from eight US managed care
organizations participating in the Vaccine Safety Datalink,
however, found that over the 5-year period following
approval of the quadrivalent HPV vaccine (2006–2011),
56 % of females ages 9–26 years had received at least one
vaccine dose, but only 42 % had completed the three-dose
series [40]. Given these modest vaccination rates and
generally lower prevalence of high-risk HPV in women
C30 years, including vaccination effects may not have
substantially impacted our results.
Our findings suggest that with proper management,
earlier detection of clinically relevant CIN attributable to
HPV-16/18 may improve protection against cervical can-
cer. In the POpulation-BAsed SCreening study AMsterdam
(POBASCAM), significantly more CIN 2? cases were
Fig. 4 Cost-effectiveness acceptability curve of the ICER for
primary HPV-16/18 genotyping with reflex cytology (‘HPV with
Genotyping’) versus cytology with reflex HPV testing (‘Cytology’)
At a WTP threshold of $50,000, the CEAC showed that implementing
HPV with Genotyping in primary cervical screening was more likely
to be considered cost effective (more effective and meeting the WTP
criteria) than Cytology. CEAC cost-effectiveness acceptability curve,
HPV human papillomavirus, ICER incremental cost-effectiveness
ratio, WTP willingness-to-pay
Table 5 Results of threshold analyses of selected model parameters in one-way sensitivity analyses
Variable Base value Threshold value at which HPV with genotyping is less
cost effectivea than the comparator strategy
Cytology
Cytology, sensitivity 56.1 % [97.7 %
HPV with genotyping, sensitivity 72.0 % \35.6 %
Annual discount rate, effects 3.0 % [17.6 %
cobas HPV test with genotyping, cost $48.24b [$148.37b
HPV HR only
HPV HR only, sensitivity 51.9 % HPV with genotyping was cost effective at all values
HPV with genotyping, sensitivity 72.0 % \34.8 %
cobas HPV test with genotyping, cost $48.24b [$151.51b
Co-testing
Co-testing, sensitivity 56.1 % HPV with genotyping was cost effective at all values
HPV with genotyping, sensitivity 72.0 % \28.9 %
cobas HPV test with genotyping, cost $48.24b [$174.18b
HPV human papillomavirus, HPV HR human papillomavirus, high-risk, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life
year, USD United States dollars
a The ICER for HPV with genotyping exceeded [$50,000/QALY (negative net monetary benefit) compared with the comparator screening
strategy
b 2013 USD
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detected at baseline in women randomized to HPV DNA
and cytology co-testing compared with those tested with
cytology only (p = 0.015) [41]. Conversely, at 5-year
follow-up, significantly fewer HPV-16–positive CCIN 3
lesions were detected with co-testing compared with
cytology-based ASC-US triage (p = 0.012). Detection of
non-HPV-16–positive CCIN 3 did not differ between
groups. These results support the utility of HPV testing in
primary screening for women aged C30 years.
Despite technological advancements, the goals of cer-
vical cancer screening have remained unchanged and aim
to identify as many women at risk for cancer as possible,
while protecting others against potential harms of unnec-
essary interventions. Strategies employing a highly sensi-
tive HPV test in primary screening must be balanced with a
more specific test (such as cytology) to ensure that the right
women receive appropriate interventions. Incorporating
such a strategy, however, must account for the population
screened as well as economic considerations. A Dutch
simulation cost-effectiveness model evaluating nine pri-
mary screening strategies concluded that HPV screening
was preferred for women aged [30 years in many sce-
narios simulating screening situations in Europe [42]. In
contrast, primary cytology was preferred only in scenarios
bearing high HPV prevalence and high HPV testing costs
[42]. For developing countries where screening effective-
ness was suboptimal, the World Health Organization rec-
ommended screening in focused geographies and in high-
risk women (aged 35–49 years or 30–50 years) once or
twice in their lifetime, using a highly sensitive test with
high coverage of the targeted population [43].
HPV with Genotyping may detect clinically relevant
high-grade CIN earlier and facilitate efficient use of
healthcare resources in the long run. Detecting disease at the
initial visit may also optimize protection against cervical
cancer. Further analyses of women screened in real-world
settings may assist in confirming the cost effectiveness of
HPV-16/18 genotyping in primary cervical screening.
Acknowledgments The authors acknowledge Lionel Pinto and
Trent McLaughlin, PhD for their contributions to conceptualization of
the manuscript and to the review and testing of the cost-effectiveness
analysis model.
Conflict of interest statements This analysis was funded by Roche
Molecular Diagnostics. Dr. Huh is a non-paid consultant to Roche
Molecular Diagnostics and is on the Advisory Boards for Hologic,
Inc. and Becton Dickinson. J. Huang and N. Poulios are employees of
Roche Molecular Diagnostics. E. Williams and T. Bramley are paid
consultants to Roche Molecular Diagnostics.
Author contributions W Huh is the guarantor for the manuscript
content. W. Huh, E. Williams, and J. Huang contributed to the
development and design of the economic model, selection of data
sources, and analyses. All authors participated in the writing, critical
review, editing, and approval of the manuscript for submission.
References
1. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, May-
rand MH, et al. Overview of human papillomavirus-based and other
novel options for cervical cancer screening in developed and
developing countries. Vaccine. 2008;26(Suppl 10):K29–41.
2. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner
J. Chapter 9: Clinical applications of HPV testing: a summary of
meta-analyses. Vaccine. 2006;24(Suppl 3):S3/78–89.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X,
Shah KV, et al. Epidemiologic classification of human papillo-
mavirus types associated with cervical cancer. N Engl J Med.
2003;348(6):518–27.
4. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle
PE. Human papillomavirus genotype distributions: implications
for vaccination and cancer screening in the United States. J Natl
Cancer Inst. 2009;101(7):475–87.
5. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M,
Scott DR, et al. The elevated 10-year risk of cervical precancer
and cancer in women with human papillomavirus (HPV) type 16
or 18 and the possible utility of type-specific HPV testing in
clinical practice. J Natl Cancer Inst. 2005;97(14):1072–9.
6. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL,
Behrens CM. Performance of carcinogenic human papillomavirus
(HPV) testing and HPV16 or HPV18 genotyping for cervical
cancer screening of women aged 25 years and older: a subanal-
ysis of the ATHENA study. Lancet Oncol. 2011;12(9):880–90.
7. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Jr.,
Cuzick J. Comparison of cervical cancer screening strategies
incorporating different combinations of cytology, HPV testing,
and genotyping for HPV 16/18: results from the ATHENA HPV
study. Am J Obstet Gynecol. 2012;208(3):184e1–e11.
8. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D,
Wheeler CM. A 2-year prospective study of human papilloma-
virus persistence among women with a cytological diagnosis of
atypical squamous cells of undetermined significance or low-
grade squamous intraepithelial lesion. J Infect Dis.
2007;195(11):1582–9.
9. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam
SL, Cain J, et al. American Cancer Society, American Society for
Colposcopy and Cervical Pathology, and American Society for
Clinical Pathology screening guidelines for the prevention and
early detection of cervical cancer. CA Cancer J Clin.
2012;62(3):147–72.
10. Perkins RB, Anderson BL, Gorin SS, Schulkin JA. Challenges in
cervical cancer prevention: a survey of U.S. obstetrician-gyne-
cologists. Am J Prev Med. 2013;45(2):175–81.
11. Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh
WK. Cost-effectiveness of using human papillomavirus 16/18
genotype triage in cervical cancer screening. Gynecol Oncol.
2010;119(2):237–42.
12. Wright TC, Jr., Stoler MH, Behrens CM, Apple R, Derion T,
Wright TL. The ATHENA human papillomavirus study: design,
methods, and baseline results. Am J Obstet Gynecol.
2012;206(1):46e1–e11.
13. Brismar-Wendel S, Froberg M, Hjerpe A, Andersson S, Johans-
son B. Age-specific prevalence of HPV genotypes in cervical
cytology samples with equivocal or low-grade lesions. Br J
Cancer. 2009;101:511–7.
14. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV-type
distribution in women with and without cervical neoplastic dis-
eases. Vaccine. 2006;2006(24S):S3/26–S3/34.
15. Cuzick J, Cox T, Zhang G, et al. Human papillomavirus testing
for triage of women with low-grade squamous lesions. Int J
Cancer. 2013;132(4):959–66.
106 W. K. Huh et al.
16. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The
estimated direct medical cost of sexually transmitted diseases
among American youth, 2000. Perspect Sex Reprod Health.
2004;36(1):11–9.
17. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of
changes in cervical screening practice in the UK: results from a
modelling study. Br J Cancer. 2004;91(3):530–6.
18. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco
E. A comprehensive natural history model of HPV infection and
cervical cancer to estimate the clinical impact of a prophylactic
HPV-16/18 vaccine. Int J Cancer. 2003;106(6):896–904.
19. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine
for human papillomavirus. Emerg Infect Dis. 2003;9(1):37–48.
20. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB.
Mathematical model for the natural history of human papillo-
mavirus infection and cervical carcinogenesis. Am J Epidemiol.
2000;151(12):1158–71.
21. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Pro-
gression and regression of incident cervical HPV 6, 11, 16 and 18
infections in young women. Infect Agent Cancer. 2007;2:15.
22. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE,
Zhang T, et al. Persistence of type-specific human papillomavirus
infection among cytologically normal women. J Infect Dis.
1994;169(2):235–40.
23. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital
human papillomavirus infection and neoplasia. J Natl Cancer Inst
Monogr. 2003;31:14–9.
24. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M,
Kim JJ. Modeling preventative strategies against human papil-
lomavirus-related disease in developed countries. Vaccine.
2012;30(Suppl 5):F157–67.
25. Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S,
et al. Cervical cancer screening in Australia: modelled evaluation
of the impact of changing the recommended interval from two to
three years. BMC Public Health. 2010;10:734.
26. Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Is-
kandar R, et al. Methods of model calibration: observations from
a mathematical model of cervical cancer. Pharmacoeconomics.
2010;28(11):995–1000.
27. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International
incidence rates of invasive cervical cancer before cytological
screening. Int J Cancer. 1997;71(2):159–65.
28. Altekruse S, Kosary C, Krapcho M, et al. SEER cancer statistics
review, 1975–2007. Bethesda, MD: National Cancer Institute;
2010 (based on November 2009 data submission). Available
http://seer.cancer.gov/csr/1975_2007. 2010.
29. Denny L, Wright TC. Glob. libr. women’s med. Strategies for
overcoming the barriers to cervical cancer screening in low-
resource settings (ISSN: 1756-2228). 2009. doi:10.3843/
GLOWM.10022.
30. Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L,
Strander B, et al. Screening and cervical cancer cure: population
based cohort study. Bmj. 2012;344:e900.
31. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK,
Schiffman M, et al. 2012 updated consensus guidelines for the
management of abnormal cervical cancer screening tests and
cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl
1):S1–27.
32. Guedes AC, Zeferino LC, Syrjanen KJ, Brenna SM. Short-term
outcome of cervical intraepithelial neoplasia grade 2: consider-
ations for management strategies and reproducibility of diagno-
sis. Anticancer Res. 2010;30(6):2319–23.
33. Stratton KR, Durch JS, Lawrence RS, editors. Committee to
Study Priorities for Vaccine Development Division of Health
Promotion and Disease Prevention Institute of Medicine. Vac-
cines for the 21st century: a tool for decisionmaking. Washing-
ton: National Academies Press; 2000.
34. Severens JL, Milne RJ. Discounting health outcomes in economic
evaluation: the ongoing debate. Value Health. 2004;7(4):
397–401.
35. Smith DH, Gravelle H. The practice of discounting in economic
evaluations of healthcare interventions. Int J Technol Assess
Health Care. 2001;17(2):236–43.
36. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ,
Paltiel AD. Model parameter estimation and uncertainty: a report
of the ISPOR-SMDM Modeling Good Research Practices Task
Force-6. Value Health. 2012;15(6):835–42.
37. Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG,
Ceballos K, et al. Primary cervical cancer screening with HPV
testing compared with liquid-based cytology: results of round 1 of
a randomised controlled trial—the HPV FOCAL Study. Br J
Cancer. 2012;107(12):1917–24.
38. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-
specific incidence of cervical cancer after correction for hyster-
ectomy prevalence in the United States from 2000 to 2009.
Cancer. 2014;120(13):2032–8.
39. From the Centers for Disease Control. Hysterectomy prevalence,
cervical cancer deaths. Jama. 1992;267(7):914.
40. Schmidt MA, Gold R, Kurosky SK, Daley MF, Irving SA, Gee J,
et al. Uptake, coverage, and completion of quadrivalent human
papillomavirus vaccine in the vaccine safety Datalink, July 2006–
June 2011. J Adolesc Health. 2013;53(5):637–41.
41. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulk-
mans NW, Heideman DA, et al. Human papillomavirus testing
for the detection of high-grade cervical intraepithelial neoplasia
and cancer: final results of the POBASCAM randomised con-
trolled trial. Lancet Oncol. 2012;13(1):78–88.
42. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner
T, et al. Primary screening for human papillomavirus compared
with cytology screening for cervical cancer in European settings:
cost effectiveness analysis based on a Dutch microsimulation
model. BMJ. 2012;344:e670.
43. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective
screening programmes for cervical cancer in low- and middle-
income developing countries. Bull World Health Organ.
2001;79(10):954–62.
HPV-16/18 Genotyping in Cervical Cancer Screening 107
